New study maps hidden breast cancer subtype in gulf women

NCT ID NCT06125314

Completed Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked back at medical records of 517 women in Gulf countries with advanced breast cancer that was previously labeled HER2-negative. Researchers re-tested old tumor samples to find out how many actually have HER2-low breast cancer, a newer subtype. The goal is to better understand how common it is and how it behaves, which could improve future diagnosis and care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors better identify and understand HER2-low breast cancer, potentially leading to more personalized treatment approaches in the future.
What could go wrong: This is a retrospective chart review, not a treatment trial, so it cannot prove any new therapy works. The results may not apply outside the Gulf region.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER BREAST CARCINOMA BREAST NEOPLASMS GENES HER2

Contacts and locations

Show contact details

Locations

Research Site

Kuwait City, Kuwait
Research Site

Doha, Qatar
Research Site

Mecca, Saudi Arabia, Saudi Arabia
Research Site

Riyadh, Saudi Arabia
Research Site

Abu Dhabi, United Arab Emirates
Research Site

Al Ain City, United Arab Emirates
Research Site

Dubai, United Arab Emirates

More trials for these conditions

Other studies related to the condition(s) this trial covers.